Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints.